Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[haysaw]

I don't see any likely issue with either IND (FDA or Europe) for Ph1 clinical studies. The timing will be interesting as it relates to the Nasdaq qualifications, and the push for shareholder approval of a potential R/S. In all honesty, the actual confirmation of go ahead for clinical studies doesn't mean much at all, but I guess it does remove some perceived uncertainty.